Katherine Menson, DO
Critical Care Medicine · Burlington, VTNPI 1386986974
Payments from drug & device makers
Across 53 payments — averaging $5480.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$190K
- Chiesi USA, Inc.$77K
- AstraZeneca$22K
- Genentech USA, Inc.$2K
- CSL Behring$13
What the payments were for
- Travel & lodging$4,30797%
- Food & beverage$1133%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 27 | $189,651 |
| Chiesi USA, Inc. | 18 | $77,240 |
| AstraZeneca | 1 | $21,785 |
| Genentech USA, Inc. | 6 | $1,802 |
| CSL Behring | 1 | $13 |
How this compares
Too few critical care medicine providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 17 | $81,900 |
| XolairOmalizumab | 26 | $74,071 |
| TezspireTezepelumab-Ekko | 14 | $61,538 |
| Dupixent PenDupilumab | 16 | $57,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $43,317 |
| DuleraMometasone/Formoterol | 54 | $25,794 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,304 |
| Spiriva RespimatTiotropium Bromide | 25 | $16,125 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,402 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $10,580 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $7,697 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,856 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,669 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,932 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $189,651 | $74,07126 claims |
| AstraZenecaTezspire, Symbicort | $21,785 | $72,11853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Vermonton file to place this against a meaningful peer group, so we don't.
Other critical care medicine in Burlington
- Renee StapletonBurlington$178K
- David KaminskyBurlington$45K
- John KlickBurlington$5K
- Katelin MorrissetteBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.